Rona Therapeutics Completes First Cohort Dosing in First-in-Human Phase 1 Clinical Trial of Obesity Treatment RN3161
December 16, 2025
Source: drugdu
30
Rona Therapeutics announced on December 15, 2025, that Cohort 1 dosing for their RN3161 drug, a GalNAc-conjugated siRNA targeting INHBE for obesity, had been completed in its Phase 1 clinical trial. Initial data from this cohort indicated good safety and tolerability, reaching a clinical milestone for the company's INHBE program. Completion of dosing for the remaining cohorts is expected in 2026.
https://finance.eastmoney.com/a/202512153592095373.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- FDA Approves Lerochol for Adults with Elevated LDL Cholesterol December 16, 2025
- How to Head Off Tendon Trouble December 16, 2025
- Ascletis Pharma’s ASC50 Phase I clinical trial in the United States yielded positive topline results December 16, 2025
- Hualan Biological’s application for clinical trial of pembrolizumab injection has been accepted December 16, 2025
- Another Phase 3 clinical trial failed. December 16, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
